The drug was originally developed for people with late-stage dementia but was found to be ineffective. However researchers noticed that it was having an impact on people with mild symptoms. The breakthrough is significant because tests are in development which could pick up Alzheimer’s 10 years before the first symptoms emerge, meaning that treatment could start very early and perhaps prevent the plaques ever forming.